| Members |
targetComponentId |
| Saphenous vein graft replacement of four or more coronary arteries |
Aortocoronary artery bypass of four or more coronary arteries with saphenous vein graft (procedure) |
| Saphenous vein graft replacement of one coronary artery |
Aortocoronary artery bypass of one coronary artery with saphenous vein graft (procedure) |
| Saphenous vein graft replacement of three coronary arteries |
Aortocoronary artery bypass of three coronary arteries with saphenous vein graft (procedure) |
| Saphenous vein graft replacement of two coronary arteries |
Aortocoronary artery bypass of two coronary arteries with saphenous vein graft (procedure) |
| Saquinavir 200mg capsule |
Saquinavir (as saquinavir mesilate) 200 mg oral capsule |
| Saquinavir 500mg tablet |
Saquinavir (as saquinavir mesilate) 500 mg oral tablet |
| Saquinavir mesylate 200mg capsule |
Saquinavir (as saquinavir mesilate) 200 mg oral capsule |
| Saquinavir mesylate 200mg capsule |
Saquinavir (as saquinavir mesilate) 200 mg oral capsule |
| Sarcoidosis, anular type |
Annular sarcoidosis (disorder) |
| Sarcoma - category |
Sarcoma (morphologic abnormality) |
| Sarcoma, no International Classification of Diseases for Oncology subtype |
Sarcoma (morphologic abnormality) |
| Sargramostim 250mcg injection |
Product containing precisely sargramostim 250 microgram/1 vial powder for conventional release solution for injection (clinical drug) |
| Satyriasis |
Excessive sexual drive |
| Savinase specific extract |
Product containing savinase (medicinal product) |
| Scaling |
Desquamation |
| Scallop - dietary |
Scallop (substance) |
| Scalp flap |
Flap (substance) |
| Scalp random pattern flap |
Random pattern flap |
| Scalpel wound as birth trauma |
Accidental laceration during a procedure |
| plaie par scalpel due à un traumatisme à la naissance |
Accidental laceration during a procedure |
| Scanning |
Action |
| Scanning-tunnelling |
Action |
| Scapular axial pattern flap |
Axial pattern flap |
| Scapular fasciocutaneous flap |
Fasciocutaneous flap |
| Scapular fasciocutaneous flap plus scapula |
Osteofasciocutaneous flap (substance) |
| Scapulohumeral fibrositis |
Scapulohumeral fibrositis |
| Scar of posterior pole of retina |
Scar of posterior pole of retina (disorder) |
| Scarring |
Scar |
| Schistosome |
Schistosoma |
| Schizophrenic relative |
FH: Schizophrenia |
| Schmidt's syndrome |
Polyglandular autoimmune syndrome, type 2 |
| Schmorl's nodes of other region, NEC |
Schmorl's nodes (disorder) |
| Schonell graded word reading test |
Schonell graded reading test (assessment scale) |
| Schonell graded word spelling test |
Schonell graded spelling test (assessment scale) |
| School maladjustment |
School maladjustment |
| Scleroderma NOS |
Scleroderma |
| Scleroderma NOS |
Scleroderma |
| Scleroderma syndrome |
Scleroderma |
| Scoliosis |
Congenital postural scoliosis |
| Scopolamine 0.5mg/24 hr patch |
Product containing only scopolamine in transdermal dose form (medicinal product form) |
| Scopolamine hydrobromide 0.25% solution |
Product containing precisely scopolamine (as scopolamine hydrobromide) 2.5 milligram/1 milliliter conventional release eye solution (clinical drug) |
| Scopulariopsis koningii |
Scopulariopsis brevicaulis |
| Screening for drug of abuse in blood specimen positive |
Blood substance level above reference range |
| Screening for drug of abuse in urine specimen positive |
Substance in urine detected by screening method (finding) |
| Screenwash |
Automotive screenwash |
| Screwing - action |
Insertion - action (qualifier value) |
| Screws up eyes |
Inappropriate movement of face |
| Screws up face |
Inappropriate movement of face |
| Scrofula |
Scrofuloderma |
| Scrotal flap |
Flap (substance) |
| Sebaceous epithelioma |
Sebaceous adenoma |
| milieu retiré |
Secluded environment (finding) |
| parent(e) par le sang du deuxième degré de la personne concernée |
Second degree blood relative (person) |
| Second degree female blood relative of subject |
Second degree female blood relative (person) |
| vaccination combinée contre la diphtérie et le tétanos, deuxième dose |
Administration of second dose of diphtheria and tetanus vaccine |
| Second diphtheria and tetanus double vaccination |
Administration of second dose of diphtheria and tetanus vaccine |
| vaccination par le vaccin triple contre la diphtérie, le tétanos et la coqueluche, deuxième dose |
Administration of second dose of diphtheria, pertussis, and tetanus vaccine |
| Second diphtheria, pertussis and tetanus triple vaccination |
Administration of second dose of diphtheria, pertussis, and tetanus vaccine |
| Second glass clear |
Second glass clear |
| Second glass contains mucous |
Second glass contains mucous (finding) |
| Second glass contains specks or sediments |
Second glass contains specks or sediments |
| Second glass contains threads or strands |
Second glass contains threads or strands |
| Second toe flap |
Flap (substance) |
| Secondary and unspec malig neop pulmonary lymph nodes |
Metastatic malignant neoplasm to lymph node |
| Secondary dedifferentiated intraosseous ameloblastic carcinoma |
Dedifferentiated intraosseous ameloblastic carcinoma (morphologic abnormality) |
| Secondary dedifferentiated peripheral ameloblastic carcinoma |
Dedifferentiated peripheral ameloblastic carcinoma |
| maladie secondaire |
Disease |
| Secondary hemorrhage due to and following illegally induced termination of pregnancy |
Secondary haemorrhage due to and following induced termination of pregnancy |
| Secondary hemorrhage due to and following legally induced termination of pregnancy |
Secondary haemorrhage due to and following induced termination of pregnancy |
| Secondary hyperoxaluria |
Secondary oxalosis |
| Secondary hypogonadism |
Hypogonadotropic hypogonadism |
| Secondary idiopathic telangiectasia |
Secondary telangiectasia (disorder) |
| Secondary localized osteoarthrosis of thigh |
Disorder of lower extremity (disorder) |
| Secondary malignant neoplasm of small intestine and duodenum |
Metastatic malignant neoplasm to small intestine |
| Secondary malignant neoplastic process |
Neoplasm, metastatic |
| Secondary nephrogenic diabetes insipidus |
Nephrogenic diabetes insipidus |
| Secondary operation NOC |
Surgical procedure (procedure) |
| Secondary osteosarcoma |
Secondary osteosarcoma following treatment or precursor disease (morphologic abnormality) |
| Secondary syphilis of other viscera |
Secondary syphilis of viscera |
| Secondary transvestism |
Secondary transvestism (finding) |
| Secretin 40mcg powder for injection solution vial |
Product containing only secretin in parenteral dose form (medicinal product form) |
| Secretory otitis media |
Chronic mucoid otitis media |
| Sedating antihistamine |
Histamine receptor antagonist |
| Sedating antihistamine adverse reaction |
Adverse reaction to antihistamines |
| Sedative dependence |
Sedative dependence (disorder) |
| Sedative dependence with current use |
Sedative dependence (disorder) |
| Seizure co-occurrent and due to drug withdrawal |
Seizure co-occurrent and due to substance withdrawal |
| Seizure disorder clinical management plan |
Seizure disorder clinical management plan |
| Seizure undetermined whether focal or generalized |
Epileptic seizure |
| Sejongia antarctica |
Chryseobacterium antarcticum (organism) |
| Sejongia jeonii |
Chryseobacterium jeonii (organism) |
| Selegiline 1.25mg orally disintegrating tablet |
Product containing precisely selegiline hydrochloride 1.25 milligram/1 each conventional release orodispersible tablet (clinical drug) |
| Selegiline 12mg/24hours transdermal patch |
Selegiline 500 microgram/hour prolonged-release transdermal patch |
| Selegiline 6mg/24hours transdermal patch |
Product containing precisely selegiline 250 microgram/1 hour prolonged-release transdermal patch (clinical drug) |
| Selegiline 9mg/24hours transdermal patch |
Selegiline 375 microgram/hour prolonged-release transdermal patch |
| Selenium 100micrograms/2mL oral solution |
Product containing only selenium in oral dose form (medicinal product form) |
| Selenium 100micrograms/2mL solution for injection |
Product containing only selenium in parenteral dose form (medicinal product form) |
| Selenium 500micrograms/10mL oral solution |
Product containing only selenium in oral dose form (medicinal product form) |
| Selenium 500micrograms/10mL solution for injection |
Product containing only selenium in parenteral dose form (medicinal product form) |
| Self poisoning by agricultural chemical |
Self poisoning by herbicide (disorder) |
| Self poisoning by non-drug solid or liquid agents |
Self-administered poisoning |
FHIR